The FDA approved asundexian with antiplatelet therapy after non-cardioembolic ischemic stroke or high-risk TIA, based on OCEANIC-STROKE data.
News|Articles|May 30, 2024
Learn about the procedure that saved Maverick.
Advertisement
Dr. Emile Bacha, Director of Congenital Pediatric Cardiac Surgery at NewYork‑Presbyterian Morgan Stanley Children's Hospital, collaborated with a multidisciplinary team of specialists to repair a complex case of "Swiss Cheese" septum.
Advertisement
Related to this article
Clinicians at ACAAI 2026 will see late-breaking HAE, anaphylaxis, urticaria, and food allergy data, plus exclusive expert interviews.
Mona Shahriari, MD, and Valerie D. Callender, MD, discuss trial diversity, better outcome measures, and how investigators can earn patient trust.
Compass Pathways completed its NDA for COMP360 based on 2 phase 3 trials and a phase 2b study in > 1000 participants with highly chronic TRD.
In a UCB-funded network meta-analysis of 17 trials, bimekizumab ranked first on HiSCR50, HiSCR75, and IHS4-55 among HS drugs at Weeks 12 - 16.
The 2027 GOLD report recommends a LAMA for group A, defines 6 pre-COPD types, and expands CT, rehabilitation, and cardiovascular guidance for COPD.
Topline results presented at The Liver Meeting showed 79% of patients with HDV reached undetectable HDV RNA at 48 weeks with monthly elebsiran plus tobevibart.
Kausik Ray, MD, MBChB, MPhil, discusses Lp(a)HORIZON, remnant cholesterol targets, enlicitide, and the lipid outcome trials to watch in 2027.
Advertisement
Advertisement
Trending on HCPLive
1
Single Dose of CIDEB siRNA Normalizes Liver Fat in MASLD Through 36 Weeks
2
Lp(a)HORIZON, Oral PCSK9s, and 2027 Lipid Trials, with Kausik Ray, MD, MBChB, MPhil
3
COMP360 Psilocybin NDA Submitted to FDA for Treatment-Resistant Depression
4
Elebsiran Plus Tobevibart Suppresses HDV RNA in Phase 3 ECLIPSE 1 Trial
5